US Congress House Bill 1353 (Prior Session Legislation)

---

Spectrum: Bipartisan Bill
Status: Introduced on March 13 2015 - 25% progression, died in committee
Action: 2015-03-20 - Referred to the Subcommittee on Health.
Pending: House Subcommittee on Health Committee
Text: Latest bill text (Introduced) [PDF]

PATIENT Act of 2015 Promoting Access for Treatments Ideal in Enhancing New Therapies Act of 2015 This bill amends the Federal Food, Drug, and Cosmetic Act to extend to five years the three-year marketing exclusivity period provided to certain new drugs that include an active ingredient that was already approved by the Food and Drug Administration. A drug is provided this extended exclusivity period if it is approved for a new indication or use, or the drug has been reformulated or redesigned to: promote greater patient adherence to an approved treatment regime, reduce the public health risks associated with the drug, reduce side effects or adverse events, provide benefits to the health-care system, or provide other comparable patient benefits.

PATIENT Act of 2015 Promoting Access for Treatments Ideal in Enhancing New Therapies Act of 2015

Rep. Gus Bilirakis [R-FL]	Rep. Gerald Connolly [D-VA]	Rep. Steve Israel [D-NY]	Rep. Morgan Griffith [R-VA]
Rep. Susan Brooks [R-IN]

Date	Chamber	Action
2015-03-20	House	Referred to the Subcommittee on Health.
2015-03-13	House	Referred to the House Committee on Energy and Commerce.
2015-03-13	House	Introduced in House

Type	Source
Summary	https://www.congress.gov/bill/114th-congress/house-bill/1353/all-info
Text	https://www.congress.gov/114/bills/hr1353/BILLS-114hr1353ih.pdf